• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients.

作者信息

Stroes Erik S, Nierman Melchior C, Meulenberg Janneke J, Franssen Remco, Twisk Jaap, Henny C Pieter, Maas Mario M, Zwinderman Aeilko H, Ross Colin, Aronica Eleonora, High Katherine A, Levi Marcel M, Hayden Michael R, Kastelein John J, Kuivenhoven Jan Albert

机构信息

Vascular Medicine, AMC, the Netherlands.

出版信息

Arterioscler Thromb Vasc Biol. 2008 Dec;28(12):2303-4. doi: 10.1161/ATVBAHA.108.175620. Epub 2008 Sep 18.

DOI:10.1161/ATVBAHA.108.175620
PMID:18802015
Abstract
摘要

相似文献

1
Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients.肌肉注射AAV1-脂蛋白脂肪酶S447X可降低脂蛋白脂肪酶缺乏症患者的甘油三酯水平。
Arterioscler Thromb Vasc Biol. 2008 Dec;28(12):2303-4. doi: 10.1161/ATVBAHA.108.175620. Epub 2008 Sep 18.
2
Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPL(S447X) beneficial mutation.通过AAV1介导的天然存在的有益突变LPL(S447X)基因转移对小鼠脂蛋白脂肪酶缺乏症进行长期纠正。
Hum Gene Ther. 2004 Sep;15(9):906-19. doi: 10.1089/hum.2004.15.906.
3
Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy.在脂蛋白脂肪酶缺乏基因治疗的II期临床试验中，对肌肉注射阿利波基因替帕罗韦（AAV1-LPL(S447X)）的免疫反应。
Hum Gene Ther. 2014 Mar;25(3):180-8. doi: 10.1089/hum.2013.169. Epub 2014 Feb 28.
4
Gene therapy for lipoprotein lipase deficiency: working toward clinical application.脂蛋白脂肪酶缺乏症的基因治疗：迈向临床应用
Hum Gene Ther. 2005 Nov;16(11):1276-86. doi: 10.1089/hum.2005.16.1276.
5
Gene therapy for genetic lipid disorders: lipoprotein lipase deficiency as a paradigm.遗传性脂质紊乱的基因治疗：以脂蛋白脂肪酶缺乏症为例
Neth J Med. 2005 Jan;63(1):2-3.
6
Alipogene tiparvovec, an adeno-associated virus encoding the Ser(447)X variant of the human lipoprotein lipase gene for the treatment of patients with lipoprotein lipase deficiency.阿利泼金替帕罗韦克，一种编码人脂蛋白脂肪酶基因Ser(447)X变体的腺相关病毒，用于治疗脂蛋白脂肪酶缺乏症患者。
Curr Opin Mol Ther. 2009 Dec;11(6):681-91.
7
Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency.脂蛋白脂肪酶缺乏症的阿利泼金替帕罗韦基因疗法临床开发综述。
Atheroscler Suppl. 2010 Jun;11(1):55-60. doi: 10.1016/j.atherosclerosissup.2010.03.004. Epub 2010 Apr 27.
8
Gene therapy for genetic lipoprotein lipase deficiency: from promise to practice.针对遗传性脂蛋白脂肪酶缺乏症的基因治疗：从前景到实践。
Neth J Med. 2005 Jan;63(1):14-9.
9
Alipogene tiparvovec for the treatment of lipoprotein lipase deficiency.阿利泼金替帕罗韦克用于治疗脂蛋白脂肪酶缺乏症。
Drugs Today (Barc). 2013 Mar;49(3):161-70. doi: 10.1358/dot.2013.49.3.1937398.
10
Gene therapy enters the pharma market: the short story of a long journey.基因疗法进入制药市场：漫长征程的简短故事。
EMBO Mol Med. 2013 Jan;5(1):1-3. doi: 10.1002/emmm.201202291.

引用本文的文献

1
Optimization of adeno-associated viral (AAV) gene therapies vectors for balancing efficacy, longevity and safety for clinical application.优化腺相关病毒（AAV）基因治疗载体以平衡临床应用中的疗效、持久性和安全性。
Gene Ther. 2025 Mar 26. doi: 10.1038/s41434-025-00524-x.
2
Precision Genome Editing Techniques in Gene Therapy: Current State and Future Prospects.基因治疗中的精确基因组编辑技术：现状与未来展望。
Curr Gene Ther. 2024;24(5):377-394. doi: 10.2174/0115665232279528240115075352.
3
Preclinical evaluation of the efficacy and safety of AAV1-hOTOF in mice and nonhuman primates.
AAV1-hOTOF在小鼠和非人类灵长类动物中的疗效和安全性的临床前评估。
Mol Ther Methods Clin Dev. 2023 Nov 10;31:101154. doi: 10.1016/j.omtm.2023.101154. eCollection 2023 Dec 14.
4
AAV-mediated hepatic LPL expression ameliorates severe hypertriglyceridemia and acute pancreatitis in Gpihbp1 deficient mice and rats.腺相关病毒介导的肝脏脂蛋白脂肪酶表达可改善Gpihbp1基因缺陷小鼠和大鼠的严重高甘油三酯血症及急性胰腺炎。
Mol Ther. 2024 Jan 3;32(1):59-73. doi: 10.1016/j.ymthe.2023.11.018. Epub 2023 Nov 15.
5
Development of new adeno-associated virus capsid variants for targeted gene delivery to human cardiomyocytes.用于将基因靶向递送至人心肌细胞的新型腺相关病毒衣壳变体的研发。
Mol Ther Methods Clin Dev. 2023 Aug 18;30:459-473. doi: 10.1016/j.omtm.2023.08.010. eCollection 2023 Sep 14.
6
Rationale and strategies for the development of safe and effective optimized AAV vectors for human gene therapy.用于人类基因治疗的安全有效优化腺相关病毒载体开发的原理与策略
Mol Ther Nucleic Acids. 2023 May 17;32:949-959. doi: 10.1016/j.omtn.2023.05.014. eCollection 2023 Jun 13.
7
Molybdenum Cofactor Deficiency in Humans.钼辅因子缺陷症。
Molecules. 2022 Oct 14;27(20):6896. doi: 10.3390/molecules27206896.
8
CRISPR/Cas systems usher in a new era of disease treatment and diagnosis.CRISPR/Cas系统开创了疾病治疗与诊断的新时代。
Mol Biomed. 2022 Oct 14;3(1):31. doi: 10.1186/s43556-022-00095-y.
9
Characteristics and Outcomes of Clinical Trials on Gene Therapy in Noncongenital Cardiovascular Diseases: Cross-sectional Study of Three Clinical Trial Registries.非先天性心血管疾病基因治疗临床试验的特征与结果：三项临床试验注册库的横断面研究
JMIR Form Res. 2022 Apr 21;6(4):e33893. doi: 10.2196/33893.
10
Potential Applications for Targeted Gene Therapy to Protect Against Anthracycline Cardiotoxicity: Primer.靶向基因治疗预防蒽环类药物心脏毒性的潜在应用：入门知识
JACC CardioOncol. 2021 Dec 21;3(5):650-662. doi: 10.1016/j.jaccao.2021.09.008. eCollection 2021 Dec.